Characterization of intratumor magnetic nanoparticle distribution and heating in a rat model of metastatic spine disease.
OBJECTIVE
The goal of this study was to optimize local delivery of magnetic nanoparticles in a rat model of metastatic breast cancer in the spine for tumor hyperthermia while minimizing systemic exposure.


METHODS
A syngeneic mammary adenocarcinoma was implanted into the L-6 vertebral body of 69 female Fischer rats. Suspensions of 100-nm starch-coated iron oxide magnetic nanoparticles (micromod Partikeltechnologie GmbH) were injected into tumors 9 or 13 days after implantation. For nanoparticle distribution studies, tissues were harvested from a cohort of 36 rats, and inductively coupled plasma mass spectrometry and histopathological studies with Prussian blue staining were used to analyze the samples. Intratumor heating was tested in 4 anesthetized animals with a 20-minute exposure to an alternating magnetic field (AMF) at a frequency of 150 kHz and an amplitude of 48 kA/m or 63.3 kA/m. Intratumor and rectal temperatures were measured, and functional assessments of AMF-exposed animals and histopathological studies of heated tumor samples were examined. Rectal temperatures alone were tested in a cohort of 29 rats during AMF exposure with or without nanoparticle administration. Animal studies were completed in accordance with the protocols of the University Animal Care and Use Committee.


RESULTS
Nanoparticles remained within the tumor mass within 3 hours of injection and migrated into the bone at 6, 12, and 24 hours. Subarachnoid accumulation of nanoparticles was noted at 48 hours. No evidence of lymphoreticular nanoparticle exposure was found on histological investigation or via inductively coupled plasma mass spectrometry. The mean intratumor temperatures were 43.2°C and 40.6°C on exposure to 63.3 kA/m and 48 kA/m, respectively, with histological evidence of necrosis. All animals were ambulatory at 24 hours after treatment with no evidence of neurological dysfunction.


CONCLUSIONS
Locally delivered magnetic nanoparticles activated by an AMF can generate hyperthermia in spinal tumors without accumulating in the lymphoreticular system and without damaging the spinal cord, thereby limiting neurological dysfunction and minimizing systemic exposure. Magnetic nanoparticle hyperthermia may be a viable option for palliative therapy of spinal tumors.
Departments of Neurosurgery.
Patricia L
PL
Zadnik
Camilo A
CA
Molina
Rachel
R
Sarabia-Estrada
Mari L
ML
Groves
Michele
M
Wabler
Jana
J
Mihalic
Edward F
EF
McCarthy
Ziya L
ZL
Gokaslan
Robert
R
Ivkov
Daniel
D
Sciubba
D000230:Adenocarcinoma / Q000556:secondary* / Q000628:therapy*; D000818:Animals; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D006979:Hyperthermia, Induced; D058185:Magnetite Nanoparticles / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000473:pathology*; D011897:Random Allocation; D051381:Rats; D011916:Rats, Inbred F344; D013054:Spectrophotometry, Atomic; D013125:Spinal Neoplasms / Q000556:secondary* / Q000628:therapy*; D013535:Suspensions
D058185:Magnetite Nanoparticles; D013535:Suspensions
AMF = alternating magnetic field; BNF = Bionized Nanoferrite; ICP-MS = inductively coupled plasma mass spectrometry; PB = Prussian blue; SLP = specific loss power; VB = vertebral body; hyperthermia; iron oxide nanoparticles; magnetic nanoparticles; oncology; rat; spine; tumor